Diethyl (4-{[4-({7-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate → diethyl (4-{[4-({2-(ethylcarbamoyl)-4-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]phenyl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}benzyl)phosphonate

Participants

Reaction Steps

Prepared analogously to Compound 1B replacing Compound 1C with 2-amino-N-ethyl-5-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]benzamide (Compound 9C, 455 mg, 1.07 mmol) to afford 589 mg of the title compound (81%). 1H NMR (400 MHz, CD3OD) δ 8.42 (d, J=8.8 Hz, 1H), 8.31 (s, 1H), 8.13 (s, 1H), 7.96 (s, 1H), 7.84 (d, J=2.0 Hz, 1H), 7.68 (dd, J=2.2, 8.7 Hz, 1H), 7.55 (d, J=8.3 Hz, 2H), 7.23 (dd, J=2.6, 8.7 Hz, 2H), 4.31 (d, J=13.6 Hz, 2H), 3.97-4.08 (m, 4H), 3.57 (t, J=6.2 Hz, 2H), 3.38-3.42 (m, 2H), 3.18-3.25 (m, 2H), 2.10 (quin, J=6.5 Hz, 2H), 1.17-1.26 (m, 9H). MS (ESI): m/z 676.78 [M+H]+. UPLC: tR=1.18 min (UPLC-SQD: analytical—2 min).

Provenance & Evidence